DDInter675 DDInter1140
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]
Esmolol {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Mefloquine
Esmolol {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Esmolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Esmolol {u} (Compound) resembles {v} (Compound) Bisoprolol
Bisoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Esmolol {u} (Compound) resembles {v} (Compound) Sotalol
Sotalol {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Esmolol {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mefloquine
Esmolol {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Flecainide
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Esmolol {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Esmolol {u} (Compound) causes {v} (Side Effect) Blister
Blister {u} (Side Effect) is caused by {v} (Compound) Valproic acid
Valproic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Esmolol (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Mefloquine (Compound)
Esmolol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Mefloquine (Compound)
Esmolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Esmolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Esmolol (Compound) resembles Sotalol (Compound) and Sotalol may lead to a major life threatening interaction when taken with Mefloquine
Esmolol (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Mefloquine (Compound)
Esmolol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Flecainide (Compound) and Flecainide (Compound) resembles Mefloquine (Compound)
Esmolol (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Esmolol (Compound) causes Blister (Side Effect) and Blister (Side Effect) is caused by Valproic acid (Compound) and Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine